Skip to content
ETopical – Lifestyle
Home
Sample Page
Author:
Santhera Pharmaceuticals Holding AG
AGAMREE® (vamorolone) Data Presented at MDA 2026 Confirm Comparable Long-Term Effectiveness for up to 8 Years of Treatment, with Clinically Meaningful Safety Advantages in Duchenne Muscular Dystrophy
March 27, 2026
Full Year 2025 Trading Update
March 12, 2026
Santhera Appoints Marc Clausse as Chief Commercial Officer to Lead Next Phase of Growth
March 10, 2026
←
Previous Page
1
2